Edition:
United States

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.59EUR
17 Aug 2018
Change (% chg)

€-0.04 (-2.27%)
Prev Close
€1.63
Open
€1.63
Day's High
€1.63
Day's Low
€1.59
Volume
432,691
Avg. Vol
518,534
52-wk High
€3.93
52-wk Low
€1.40

Latest Key Developments (Source: Significant Developments)

Pharma Mar Says Chugai Terminates Licensing Agreement For Zepsyre In Japan
Friday, 27 Apr 2018 11:50am EDT 

April 27 (Reuters) - Pharma Mar SA ::SAYS SUBMITS INFORMATION REGARDING THE TERMINATION OF THE LICENSING AGREEMENT FOR JAPAN ENTERED INTO WITH CHUGAI IN RELATION TO ZEPSYRE.EFFECTIVE DATE OF TERMINATION IS IN APRIL 2019.TERMINATION DOES NOT AFFECT ANY PAYMENTS RECEIVED BY PHARMAMAR.TO INITIATE NEGOTIATIONS IN THE SHORT TERM WITH OTHER POTENTIAL LICENSEES FOR ZEPSYRE IN JAPAN.TO CONTINUE WITH PHASE I CLINICAL TRIALS INITIATED IN JAPAN IN 2017 FOR JAPANESE PATIENTS.  Full Article

Pharma Mar Q1 Net Loss Narrows To 1.3 Mln Euros YoY
Thursday, 26 Apr 2018 11:46am EDT 

April 26 (Reuters) - Pharma Mar SA ::Q1 NET LOSS 1.3 MILLION EUROS VERSUS LOSS 2.5 MILLION EUROS YEAR AGO.Q1 REVENUE 44.7 MILLION EUROS VERSUS 45.5 MILLION EUROS YEAR AGO.Q1 NEGATIVE EBITDA 888,000 EUROS VERSUS POSITIVE 70,000 EUROS YEAR AGO.  Full Article

Pharma Mar FY Net Loss Widens To 26.7 Mln Euros YoY
Wednesday, 28 Feb 2018 11:42am EST 

Feb 28 (Reuters) - PHARMA MAR SA ::FY NET LOSS 26.7 MILLION EUROS VERSUS LOSS 24.1 MILLION EUROS YEAR AGO.FY NET SALES 179.4 MILLION EUROS VERSUS 180.9 MILLION EUROS YEAR AGO.FY NEGATIVE EBITDA 7.4 MILLION EUROS.  Full Article

Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics
Wednesday, 14 Feb 2018 02:15am EST 

Feb 14 (Reuters) - PHARMA MAR SA ::LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES.SAYS WILL RECEIVE UPFRONT PAYMENT OF $5.0 MILLION ON SIGNING, FOLLOWED BY DEVELOPMENT MILESTONES IF A PRODUCT ENTERS CLINICAL DEVELOPMENT CONDUCTED BY SEATTLE GENETICS.IS ELIGIBLE FOR POTENTIAL APPROVAL AND SALES MILESTONES, ROYALTIES, ONCE PRODUCT GETS REGULATORY APPROVAL AND IS COMMERCIALIZED.  Full Article

Pharma Mar Requests Re-Examination Process For Aplidin From EMA
Wednesday, 3 Jan 2018 03:25am EST 

Jan 3 (Reuters) - PHARMA MAR SA ::REQUESTS PROCESS OF RE-EXAMINATION FOR APLIDIN FROM THE EUROPEAN MEDICINES AGENCY (EMA).AFTER FINALIZING RE-EXAMINATION PROCESS, EUROPEAN COMMISSION TO ISSUE FINAL VERDICT ON THE MARKETING AUTHORIZATION APPLICATION (MAA) FOR APLIDIN AROUND JUNE OR JULY.  Full Article

Pharma Mar Signs Distribution License Agreement For Aplidin In Israel
Tuesday, 2 Jan 2018 03:26am EST 

Jan 2 (Reuters) - PHARMA MAR SA ::SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH MEGAPHARM IN ISRAEL.  Full Article

Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment
Friday, 15 Dec 2017 06:43am EST 

Dec 15 (Reuters) - PHARMA MAR SA ::THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA.AFTER OPINION OF CHMP, EUROPEAN COMMISSION TO ISSUE FINAL DECISION, EXPECTED IN MARCH OR APRIL, 2018.  Full Article

Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue
Wednesday, 15 Nov 2017 02:12am EST 

Nov 15 (Reuters) - PHARMA MAR SA ::PHASE III TRIAL WITH ZEPSYRE IN SMALL-CELL LUNG CANCER PATIENTS (ATLANTIS) TO CONTINUE WITHOUT CHANGES ON POSITIVE RECOMMENDATION BY IDMC (INDEPENDENT DATA MONITORING COMMITTEE).  Full Article

Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma
Monday, 13 Nov 2017 02:22am EST 

Nov 13 (Reuters) - PHARMA MAR SA ::PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA.OBSERVED DISEASE CONTROL RATE AT 60 PERCENT, INCLUDING PARTIAL RESPONSES IN 12 PERCENT AND STABILIZATION IN 48 PERCENT OF CASES.‍​.  Full Article

Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment
Thursday, 9 Nov 2017 01:50am EST 

Nov 9 (Reuters) - PHARMA MAR SA ::SAID ON WEDNESDAY, EXPECTS AN OPINION RECOMMENDING AGAINST APPROVAL OF MARKETING AUTHORIZATION APPLICATION FOR APLIDIN FOR TREATMENT OF MULTIPLE MYELOMA FROM EUROPEAN MEDICINES AGENCY (EMA) BASED ON PRELIMINARY "TREND VOTE" FEEDBACK FROM AGENCY.FORMAL WRITTEN DECISION FROM EMA'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) IS EXPECTED FOLLOWING ITS DECEMBER 2017 MEETING (DEC 11 TO DEC 15).COMPANY DEEPLY SURPRISED ABOUT CHMP NEGATIVE TREND VOTE GIVEN RESULTS OF PHASE III TRIAL.CHMP NEGATIVE TREND VOTE WAS VERBALLY COMMUNICATED TO COMPANY BY EMA.  Full Article

BRIEF-Pharma Mar FY Net Loss Widens To 26.7 Mln Euros YoY

* FY NET LOSS 26.7 MILLION EUROS VERSUS LOSS 24.1 MILLION EUROS YEAR AGO